A major goal of FAU I-MED is the clinical application of new insights into disease processes and of novel immunotherapeutic approaches.
To this end, clinical trials and studies are carried out within the framework of the German Center for Immunotherapy, the National Center for Tumor Diseases (NCT-WERA, incl. Early Clinical Trial Unit) and the Bavarian Center for Cancer Research (BZKF) .
The Center of Clinical Studies (CCS) and the GMP Facilities at the University Hospital Erlangen provide the necessary regulatory and infrastructural support for cell-based immunotherapies.